Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 01 June, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 506285 | NSE: BAYERCROP

Bayer CropScience Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: May 31, 2025, 8:09 pm

Market Cap 25,519 Cr.
Current Price 5,678
High / Low 7,197/4,217
Stock P/E44.9
Book Value 634
Dividend Yield2.47 %
ROCE24.8 %
ROE19.9 %
Face Value 10.0
PEG Ratio41.01

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Bayer CropScience Ltd

Competitors of Bayer CropScience Ltd

Stock Name Market Cap Current Price High / Low Stock P/E Book Value Dividend Yield ROCE ROE Face Value
Epigral Ltd 7,680 Cr. 1,780 2,408/1,10721.5 4410.28 %25.2 %22.6 % 10.0
Dharmaj Crop Guard Ltd 804 Cr. 238 390/16523.1 1170.00 %12.0 %9.24 % 10.0
Bhaskar Agrochemicals Ltd 42.0 Cr. 80.6 122/46.110.8 34.10.00 %21.3 %24.7 % 10.0
Bhagiradha Chemicals & Industries Ltd 4,024 Cr. 310 448/185147 53.90.03 %7.44 %4.91 % 1.00
Best Agrolife Ltd 789 Cr. 334 732/24411.3 3200.90 %12.9 %9.95 % 10.0
Industry Average11,601.35 Cr1,591.9036.56435.980.33%15.27%19.95%7.25

All Competitor Stocks of Bayer CropScience Ltd

Quarterly Result

MetricMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
Sales 9631,6671,4521,0389821,7401,6179557921,6311,7381,0571,046
Expenses 7631,2721,2149527771,3151,3128276951,3171,5541,037876
Operating Profit 201395238852064253051289731418420171
OPM % 21%24%16%8%21%24%19%13%12%19%11%2%16%
Other Income 161414116242116152928243237
Interest 6483784354346
Depreciation 21231514273112151622141534
Profit before tax 19038222918419540630612410531619034168
Tax % 19%21%29%27%19%19%27%25%9%20%28%-2%15%
Net Profit 153303163134158328223939625413634143
EPS in Rs 33.9867.3336.1829.9335.2773.0949.6020.7221.3656.5630.337.6131.89

Last Updated: May 31, 2025, 6:47 am

Below is a detailed analysis of the quarterly data for Bayer CropScience Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

  • For Sales, as of Mar 2025, the value is 1,046.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,057.00 Cr. (Dec 2024) to 1,046.00 Cr., marking a decrease of 11.00 Cr..
  • For Expenses, as of Mar 2025, the value is 876.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1,037.00 Cr. (Dec 2024) to 876.00 Cr., marking a decrease of 161.00 Cr..
  • For Operating Profit, as of Mar 2025, the value is 171.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Dec 2024) to 171.00 Cr., marking an increase of 151.00 Cr..
  • For OPM %, as of Mar 2025, the value is 16.00%. The value appears strong and on an upward trend. It has increased from 2.00% (Dec 2024) to 16.00%, marking an increase of 14.00%.
  • For Other Income, as of Mar 2025, the value is 37.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Dec 2024) to 37.00 Cr., marking an increase of 5.00 Cr..
  • For Interest, as of Mar 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.00 Cr. (Dec 2024) to 6.00 Cr., marking an increase of 2.00 Cr..
  • For Depreciation, as of Mar 2025, the value is 34.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.00 Cr. (Dec 2024) to 34.00 Cr., marking an increase of 19.00 Cr..
  • For Profit before tax, as of Mar 2025, the value is 168.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Dec 2024) to 168.00 Cr., marking an increase of 134.00 Cr..
  • For Tax %, as of Mar 2025, the value is 15.00%. The value appears to be increasing, which may not be favorable. It has increased from -2.00% (Dec 2024) to 15.00%, marking an increase of 17.00%.
  • For Net Profit, as of Mar 2025, the value is 143.00 Cr.. The value appears strong and on an upward trend. It has increased from 34.00 Cr. (Dec 2024) to 143.00 Cr., marking an increase of 109.00 Cr..
  • For EPS in Rs, as of Mar 2025, the value is 31.89. The value appears strong and on an upward trend. It has increased from 7.61 (Dec 2024) to 31.89, marking an increase of 24.28.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 1:51 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 2,6823,1883,6602,7692,8032,7103,1673,6094,2614,7345,1405,1035,217
Expenses 2,3212,7683,1442,3342,3892,3002,6842,8833,4503,9234,2164,1474,603
Operating Profit 362419516435414410483726812812924956614
OPM % 13%13%14%16%15%15%15%20%19%17%18%19%12%
Other Income 1,242918882703951-646911216879114
Interest 4551071110141313222016
Depreciation 37652525293344657464807466
Profit before tax 1,563441574482448404480583794847990941645
Tax % 26%34%33%35%35%26%30%19%38%24%23%21%
Net Profit 1,162290383315291300337474493645758740521
EPS in Rs 294.1179.06104.5989.1382.3187.4198.18105.58109.72143.58168.71164.77115.86
Dividend Payout % 2%7%20%19%21%21%18%24%105%104%77%85%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)-75.04%32.07%-17.75%-7.62%3.09%12.33%40.65%4.01%30.83%17.52%-2.37%
Change in YoY Net Profit Growth (%)0.00%107.11%-49.82%10.14%10.71%9.24%28.32%-36.64%26.82%-13.31%-19.89%

Bayer CropScience Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:4%
5 Years:9%
3 Years:5%
TTM:7%
Compounded Profit Growth
10 Years:4%
5 Years:0%
3 Years:-2%
TTM:-23%
Stock Price CAGR
10 Years:4%
5 Years:2%
3 Years:2%
1 Year:13%
Return on Equity
10 Years:21%
5 Years:23%
3 Years:24%
Last Year:20%

Last Updated: Unknown

Balance Sheet

Last Updated: May 13, 2025, 2:08 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 40373735353434454545454545
Reserves 1,8921,7061,9961,8042,0211,7442,2052,5282,5052,4792,6672,8043,037
Borrowings -0-0-0-0-0-0-022686744733
Other Liabilities 4846457405977697561,3101,2621,6631,7421,8931,7012,155
Total Liabilities 2,4152,3872,7732,4372,8252,5353,5493,8364,2394,3534,6794,5975,270
Fixed Assets 219228322290342334440468425468462414516
CWIP 1272171172436475676981091192
Investments 44296850-0-0415238415463
Other Assets 2,0661,9392,4222,0622,4102,1643,0623,2703,6863,7494,0664,0104,690
Total Assets 2,4152,3872,7732,4372,8252,5353,5493,8364,2394,3534,6794,5975,270

Below is a detailed analysis of the balance sheet data for Bayer CropScience Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 45.00 Cr..
  • For Reserves, as of Sep 2024, the value is 3,037.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,804.00 Cr. (Mar 2024) to 3,037.00 Cr., marking an increase of 233.00 Cr..
  • For Borrowings, as of Sep 2024, the value is 33.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 47.00 Cr. (Mar 2024) to 33.00 Cr., marking a decrease of 14.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is 2,155.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,701.00 Cr. (Mar 2024) to 2,155.00 Cr., marking an increase of 454.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is 5,270.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,597.00 Cr. (Mar 2024) to 5,270.00 Cr., marking an increase of 673.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is 516.00 Cr.. The value appears strong and on an upward trend. It has increased from 414.00 Cr. (Mar 2024) to 516.00 Cr., marking an increase of 102.00 Cr..
  • For CWIP, as of Sep 2024, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 119.00 Cr. (Mar 2024) to 2.00 Cr., marking a decrease of 117.00 Cr..
  • For Investments, as of Sep 2024, the value is 63.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Mar 2024) to 63.00 Cr., marking an increase of 9.00 Cr..
  • For Other Assets, as of Sep 2024, the value is 4,690.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,010.00 Cr. (Mar 2024) to 4,690.00 Cr., marking an increase of 680.00 Cr..
  • For Total Assets, as of Sep 2024, the value is 5,270.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,597.00 Cr. (Mar 2024) to 5,270.00 Cr., marking an increase of 673.00 Cr..

Notably, the Reserves (3,037.00 Cr.) exceed the Borrowings (33.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +282200206157121433666687216609952262
Cash from Investing Activity +-29048516-838-113-2976483086
Cash from Financing Activity +-480-42-590-73-581-158-148-556-703-613-656-619
Net Cash Flow-488644-36776-421162489138-42479296-272

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow362.00419.00516.00435.00414.00410.00483.00724.00786.00726.00850.00909.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days444757537289817365776969
Inventory Days1069885169178175294206226235268222
Days Payable42514052676716410114212712987
Cash Conversion Cycle10894102171184197211177149185208204
Working Capital Days798853921041341167762878980
ROCE %29%24%31%25%23%22%25%30%31%31%34%34%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters71.43%71.43%71.44%71.44%71.44%71.44%71.44%71.44%71.44%71.44%71.44%71.44%
FIIs2.90%2.95%3.10%3.19%3.18%3.18%3.30%3.53%3.62%3.63%3.30%3.42%
DIIs12.90%13.10%12.76%12.78%12.74%13.06%13.23%12.70%12.80%12.47%12.08%11.69%
Public12.77%12.51%12.71%12.59%12.64%12.32%12.05%12.33%12.15%12.47%13.18%13.45%
No. of Shareholders60,23057,76057,89657,04857,25348,40445,32946,90745,85246,20151,28954,289

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Mirae Asset Large & Midcap Fund 792,954 1.33 449.55792,9542025-04-22 17:25:130%
Nippon India Small Cap Fund 531,460 0.65 301.3531,4602025-04-22 17:25:130%
Mirae Asset Midcap Fund 510,084 1.99 289.18510,0842025-04-22 17:25:140%
Aditya Birla Sun Life ELSS Tax Saver Fund 392,896 1.48 222.75392,8962025-04-22 17:25:140%
Aditya Birla Sun Life Frontline Equity Fund 329,435 0.71 186.77329,4352025-04-22 17:25:140%
Nippon India Growth Fund 303,512 0.7 172.07303,5122025-04-22 17:25:140%
HSBC Midcap Fund 294,959 1.72 167.22294,9592025-04-22 17:25:140%
Aditya Birla Sun Life MNC Fund - Div 280,976 4.49 159.3280,9762025-04-22 17:25:140%
Aditya Birla Sun Life MNC Fund - Gr 280,976 4.49 159.3280,9762025-04-22 17:25:140%
Kotak Flexicap Fund - Regular Plan 215,000 0.27 121.89215,0002025-04-22 14:53:350%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 164.77168.71143.58109.72105.58
Diluted EPS (Rs.) 164.77168.71143.58109.72105.58
Cash EPS (Rs.) 181.40186.57158.08126.19120.22
Book Value[Excl.RevalReserv]/Share (Rs.) 634.61604.03562.20568.00572.94
Book Value[Incl.RevalReserv]/Share (Rs.) 634.61604.03562.20568.00572.94
Dividend / Share (Rs.) 140.00130.00150.00115.0025.00
Revenue From Operations / Share (Rs.) 1136.571144.701054.43949.06803.88
PBDIT / Share (Rs.) 230.51220.07192.81194.99176.48
PBIT / Share (Rs.) 214.03202.36178.44178.62161.94
PBT / Share (Rs.) 209.66220.51188.60176.95129.87
Net Profit / Share (Rs.) 164.92168.86143.72109.82105.68
PBDIT Margin (%) 20.2819.2218.2820.5421.95
PBIT Margin (%) 18.8317.6716.9218.8220.14
PBT Margin (%) 18.4419.2617.8818.6416.15
Net Profit Margin (%) 14.5114.7513.6311.5713.14
Return on Networth / Equity (%) 25.9827.9525.5619.3318.44
Return on Capital Employeed (%) 32.0331.3129.7430.0526.96
Return On Assets (%) 16.1016.2014.8211.6312.37
Asset Turnover Ratio (%) 1.101.141.101.060.97
Current Ratio (X) 2.442.192.152.262.65
Quick Ratio (X) 1.481.181.241.411.80
Inventory Turnover Ratio (X) 1.481.391.822.171.65
Dividend Payout Ratio (NP) (%) 81.9374.09104.47104.8221.41
Dividend Payout Ratio (CP) (%) 74.4867.0694.9891.2218.82
Earning Retention Ratio (%) 18.0725.91-4.47-4.8278.59
Cash Earning Retention Ratio (%) 25.5232.945.028.7881.18
Interest Coverage Ratio (X) 52.8144.3167.1169.4857.42
Interest Coverage Ratio (Post Tax) (X) 38.7830.3546.4939.7344.82
Enterprise Value (Cr.) 22377.2917307.3021584.0322612.2014460.29
EV / Net Operating Revenue (X) 4.383.374.565.314.01
EV / EBITDA (X) 21.6217.5224.9325.8318.25
MarketCap / Net Operating Revenue (X) 4.613.544.735.594.30
Retention Ratios (%) 18.0625.90-4.47-4.8278.58
Price / BV (X) 8.266.708.869.346.04
Price / Net Operating Revenue (X) 4.613.544.735.594.30
EarningsYield 0.030.040.020.020.03

After reviewing the key financial ratios for Bayer CropScience Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 164.77. This value is within the healthy range. It has decreased from 168.71 (Mar 23) to 164.77, marking a decrease of 3.94.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 164.77. This value is within the healthy range. It has decreased from 168.71 (Mar 23) to 164.77, marking a decrease of 3.94.
  • For Cash EPS (Rs.), as of Mar 24, the value is 181.40. This value is within the healthy range. It has decreased from 186.57 (Mar 23) to 181.40, marking a decrease of 5.17.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 634.61. It has increased from 604.03 (Mar 23) to 634.61, marking an increase of 30.58.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 634.61. It has increased from 604.03 (Mar 23) to 634.61, marking an increase of 30.58.
  • For Dividend / Share (Rs.), as of Mar 24, the value is 140.00. This value exceeds the healthy maximum of 3. It has increased from 130.00 (Mar 23) to 140.00, marking an increase of 10.00.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 1,136.57. It has decreased from 1,144.70 (Mar 23) to 1,136.57, marking a decrease of 8.13.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 230.51. This value is within the healthy range. It has increased from 220.07 (Mar 23) to 230.51, marking an increase of 10.44.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 214.03. This value is within the healthy range. It has increased from 202.36 (Mar 23) to 214.03, marking an increase of 11.67.
  • For PBT / Share (Rs.), as of Mar 24, the value is 209.66. This value is within the healthy range. It has decreased from 220.51 (Mar 23) to 209.66, marking a decrease of 10.85.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 164.92. This value is within the healthy range. It has decreased from 168.86 (Mar 23) to 164.92, marking a decrease of 3.94.
  • For PBDIT Margin (%), as of Mar 24, the value is 20.28. This value is within the healthy range. It has increased from 19.22 (Mar 23) to 20.28, marking an increase of 1.06.
  • For PBIT Margin (%), as of Mar 24, the value is 18.83. This value is within the healthy range. It has increased from 17.67 (Mar 23) to 18.83, marking an increase of 1.16.
  • For PBT Margin (%), as of Mar 24, the value is 18.44. This value is within the healthy range. It has decreased from 19.26 (Mar 23) to 18.44, marking a decrease of 0.82.
  • For Net Profit Margin (%), as of Mar 24, the value is 14.51. This value exceeds the healthy maximum of 10. It has decreased from 14.75 (Mar 23) to 14.51, marking a decrease of 0.24.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 25.98. This value is within the healthy range. It has decreased from 27.95 (Mar 23) to 25.98, marking a decrease of 1.97.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 32.03. This value is within the healthy range. It has increased from 31.31 (Mar 23) to 32.03, marking an increase of 0.72.
  • For Return On Assets (%), as of Mar 24, the value is 16.10. This value is within the healthy range. It has decreased from 16.20 (Mar 23) to 16.10, marking a decrease of 0.10.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 1.10. It has decreased from 1.14 (Mar 23) to 1.10, marking a decrease of 0.04.
  • For Current Ratio (X), as of Mar 24, the value is 2.44. This value is within the healthy range. It has increased from 2.19 (Mar 23) to 2.44, marking an increase of 0.25.
  • For Quick Ratio (X), as of Mar 24, the value is 1.48. This value is within the healthy range. It has increased from 1.18 (Mar 23) to 1.48, marking an increase of 0.30.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.48. This value is below the healthy minimum of 4. It has increased from 1.39 (Mar 23) to 1.48, marking an increase of 0.09.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 81.93. This value exceeds the healthy maximum of 50. It has increased from 74.09 (Mar 23) to 81.93, marking an increase of 7.84.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 74.48. This value exceeds the healthy maximum of 50. It has increased from 67.06 (Mar 23) to 74.48, marking an increase of 7.42.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 18.07. This value is below the healthy minimum of 40. It has decreased from 25.91 (Mar 23) to 18.07, marking a decrease of 7.84.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 25.52. This value is below the healthy minimum of 40. It has decreased from 32.94 (Mar 23) to 25.52, marking a decrease of 7.42.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 52.81. This value is within the healthy range. It has increased from 44.31 (Mar 23) to 52.81, marking an increase of 8.50.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 38.78. This value is within the healthy range. It has increased from 30.35 (Mar 23) to 38.78, marking an increase of 8.43.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 22,377.29. It has increased from 17,307.30 (Mar 23) to 22,377.29, marking an increase of 5,069.99.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 4.38. This value exceeds the healthy maximum of 3. It has increased from 3.37 (Mar 23) to 4.38, marking an increase of 1.01.
  • For EV / EBITDA (X), as of Mar 24, the value is 21.62. This value exceeds the healthy maximum of 15. It has increased from 17.52 (Mar 23) to 21.62, marking an increase of 4.10.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.61. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 23) to 4.61, marking an increase of 1.07.
  • For Retention Ratios (%), as of Mar 24, the value is 18.06. This value is below the healthy minimum of 30. It has decreased from 25.90 (Mar 23) to 18.06, marking a decrease of 7.84.
  • For Price / BV (X), as of Mar 24, the value is 8.26. This value exceeds the healthy maximum of 3. It has increased from 6.70 (Mar 23) to 8.26, marking an increase of 1.56.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.61. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 23) to 4.61, marking an increase of 1.07.
  • For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 23) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Bayer CropScience Ltd as of June 1, 2025 is: 4,643.82

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 1, 2025, Bayer CropScience Ltd is Overvalued by 18.21% compared to the current share price 5,678.00

Intrinsic Value of Bayer CropScience Ltd as of June 1, 2025 is: 4,694.67

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 1, 2025, Bayer CropScience Ltd is Overvalued by 17.32% compared to the current share price 5,678.00

Last 5 Year EPS CAGR: 1.09%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 28.25%, which is a positive sign.
  2. The company has higher reserves (2,260.62 cr) compared to borrowings (20.62 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (3.31 cr) and profit (586.92 cr) over the years.
  1. The stock has a high average Working Capital Days of 88.42, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 165.83, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bayer CropScience Ltd:
    1. Net Profit Margin: 14.51%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 32.03% (Industry Average ROCE: 15.27%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 25.98% (Industry Average ROE: 19.95%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 38.78
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.48
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 44.9 (Industry average Stock P/E: 36.56)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Bayer Cropscience Ltd. is a Public Limited Listed company incorporated on 09/09/1958 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24210MH1958PLC011173 and registration number is 011173. Currently Company is involved in the business activities of Manufacture of insecticides, rodenticides, fungicides, herbicides. Company's Total Operating Revenue is Rs. 5473.40 Cr. and Equity Capital is Rs. 44.90 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
Agro Chemicals/PesticidesBayer House, Central Avenue, Mumbai Maharashtra 400607ir_bcsl@bayer.com
http://www.bayer.in
Management
NamePosition Held
Mr. Pankaj Ramanbhai PatelChairman & Ind.Dire (Non-Exe)
Mr. Simon Thorsten WiebuschVice Chairman & Mng.Director
Ms. Ketaki Sanat BhagwatiInd. Non-Executive Director
Mr. Sekhar NatarajanInd. Non-Executive Director
Mr. Simon Johannes BritschExecutive Director & CFO
Dr. Thomas HoffmannNon Exe.Non Ind.Director
Dr. Miriam HolsteinNon Exe.Non Ind.Director
Ms. Radhika RajanInd. Non-Executive Director

FAQ

What is the intrinsic value of Bayer CropScience Ltd?

Bayer CropScience Ltd's intrinsic value (as of 31 May 2025) is ₹4643.82 — 18.21% lower the current market price of 5,678.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 25,519 Cr. market cap, FY2025-2026 high/low of ₹7,197/4,217, reserves of 3,037 Cr, and liabilities of 5,270 Cr.

What is the Market Cap of Bayer CropScience Ltd?

The Market Cap of Bayer CropScience Ltd is 25,519 Cr..

What is the current Stock Price of Bayer CropScience Ltd as on 31 May 2025?

The current stock price of Bayer CropScience Ltd as on 31 May 2025 is 5,678.

What is the High / Low of Bayer CropScience Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Bayer CropScience Ltd stocks is ₹7,197/4,217.

What is the Stock P/E of Bayer CropScience Ltd?

The Stock P/E of Bayer CropScience Ltd is 44.9.

What is the Book Value of Bayer CropScience Ltd?

The Book Value of Bayer CropScience Ltd is 634.

What is the Dividend Yield of Bayer CropScience Ltd?

The Dividend Yield of Bayer CropScience Ltd is 2.47 %.

What is the ROCE of Bayer CropScience Ltd?

The ROCE of Bayer CropScience Ltd is 24.8 %.

What is the ROE of Bayer CropScience Ltd?

The ROE of Bayer CropScience Ltd is 19.9 %.

What is the Face Value of Bayer CropScience Ltd?

The Face Value of Bayer CropScience Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Bayer CropScience Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE